The significant positive outcome from the Phase 3 trial of paltusotine for acromegaly, with all primary and secondary endpoints met and no serious adverse events, is a strong indicator of the drug's efficacy and safety. This news directly impacts Crinetics Pharmaceuticals' stock as it not only validates the company's research and development efforts but also sets a clear path towards FDA submission and potential commercialization. The stock's surge reflects investor optimism about the drug's market potential and the company's future revenue growth.